Group 1: Earnings Performance - Chemours reported quarterly earnings of $0.13 per share, missing the Zacks Consensus Estimate of $0.19 per share, and down from $0.32 per share a year ago, representing an earnings surprise of -31.58% [1] - The company posted revenues of $1.37 billion for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.94%, compared to year-ago revenues of $1.35 billion [2] - Over the last four quarters, Chemours has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Group 2: Stock Performance and Outlook - Chemours shares have lost about 28.4% since the beginning of the year, while the S&P 500 has declined by -3.9% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is $0.57 on $1.59 billion in revenues, and $1.81 on $5.89 billion in revenues for the current fiscal year [7] Group 3: Industry Context - The Zacks Industry Rank indicates that the Chemical - Diversified sector is currently in the bottom 18% of over 250 Zacks industries, suggesting potential challenges for stocks in this category [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The current estimate revisions trend for Chemours is mixed, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6]

Financial Performance - Net Sales reached $1368 million in 1Q25, a slight increase of $6 million compared to 1Q24[7] - Adjusted EBITDA was $166 million in 1Q25, a decrease of $25 million compared to $191 million in 1Q24[7] - The company experienced a Net Loss of $4 million in 1Q25, compared to a Net Income of $54 million in 1Q24[7] - Free Cash Flow was negative $196 million in 1Q25, compared to negative $392 million in 1Q24[7] - The company returned $37 million in cash to shareholders in Q1 2025[6] Segment Performance - TSS (Thermal & Specialized Solutions) Net Sales were $466 million in 1Q25, with Adjusted EBITDA at $141 million[15] - TT (Titanium Technologies) Net Sales were $597 million in 1Q25, with Adjusted EBITDA at $50 million[15] - APM (Advanced Performance Materials) Net Sales were $294 million in 1Q25, with Adjusted EBITDA at $32 million[15] - Opteon Refrigerants experienced a 40% YoY Net Sales growth in TSS[6] Strategic Initiatives and Outlook - The company is executing its "Pathway to Thrive" three-year corporate strategy[6] - The company anticipates a low-to-mid teens percentage increase in Net Sales and a 40% to 45% sequential increase in Adjusted EBITDA for 2Q25[49, 51] - The company expects Adjusted EBITDA for full year 2025 to be in the range of $825 million to $950 million[54] - The company is expanding into the liquid cooling market, projecting a $3 billion addressable market by 2030[41]

Financial Performance - Net sales for the three months ended March 31, 2025, were $1.368 billion, a slight increase from $1.362 billion in the same period of 2024[366]. - Gross profit decreased to $236 million for the three months ended March 31, 2025, down from $284 million in 2024, reflecting a decline in profitability[366]. - The net loss for the three months ended March 31, 2025, was $4 million, compared to a net income of $54 million in the same period of 2024[366]. - The company recorded a provision for income taxes of $4 million for the three months ended March 31, 2025, down from $16 million in 2024, due to decreased profitability[379]. - For the three months ended March 31, 2025, Chemours utilized supply chain financing to accelerate the collection of $93 million in accounts receivable, compared to $17 million in the same period of 2024[416]. - Chemours experienced a decrease in cash used for operating activities, with $112 million in Q1 2025 compared to $290 million in Q1 2024, primarily due to the unwinding of year-end 2023 net working capital actions[426]. - The net loss attributable to Chemours for the same period was $45 million, compared to a loss before income taxes of $53 million[444]. Cost and Expenses - The cost of goods sold increased by $54 million (or 5%) to $1.132 billion for the three months ended March 31, 2025, primarily due to higher raw materials costs[371]. - Selling, general, and administrative expenses decreased by $14 million (or 10%) to $123 million for the three months ended March 31, 2025, attributed to lower audit-related costs[373]. - Restructuring, asset-related, and other charges rose by $29 million (over 100%) to $33 million for the three months ended March 31, 2025, due to the exit from the SPS Capstone business[375]. - Interest expense increased by $3 million (or 5%) to $66 million for the three months ended March 31, 2025, driven by higher interest rates and increased debt principal[377]. Segment Performance - For the Thermal & Specialized Solutions segment, net sales increased by $12 million (or 3%) to $466 million for the three months ended March 31, 2025, compared to $454 million in the same period in 2024[387]. - Adjusted EBITDA for the Thermal & Specialized Solutions segment decreased by $9 million (or 6%) to $141 million, with an Adjusted EBITDA margin of 30%, down from 33% in the prior year[388]. - The Titanium Technologies segment's net sales increased by $6 million (or 1%) to $597 million for the three months ended March 31, 2025, compared to $591 million in the same period in 2024[394]. - Adjusted EBITDA for the Titanium Technologies segment decreased by $19 million (or 28%) to $50 million, with an Adjusted EBITDA margin of 8%, down from 12% in the prior year[395]. - The Advanced Performance Materials segment's net sales decreased by $9 million (or 3%) to $294 million for the three months ended March 31, 2025, compared to $303 million in the same period in 2024[401]. - Adjusted EBITDA for the Advanced Performance Materials segment increased by $2 million (or 7%) to $32 million, with an Adjusted EBITDA margin of 11%, up from 10% in the prior year[402]. Cash and Liquidity - Total unrestricted cash and cash equivalents as of March 31, 2025, amounted to $464 million, with $291 million held by foreign subsidiaries[412]. - The availability under the Revolving Credit Facility as of March 31, 2025, was $623 million, net of $52 million in outstanding letters of credit[412]. - The company expects liquidity from its sources to adequately support cash needs through at least the end of May 2026[411]. - As of March 31, 2025, Chemours reported unrestricted cash and cash equivalents of $291 million held by foreign subsidiaries, with a net cash outflow of approximately $31 million from the U.S. due to intercompany loans and dividends[418]. - Current liabilities decreased by $144 million (or 8%) to $1.673 billion at March 31, 2025, with accounts payable down by $150 million (or 13%) to $1 billion[436]. - Chemours declared a quarterly cash dividend of $0.0875 per share for Q2 2025, representing a 65% decrease from the previous quarter's dividend, aligning with the company's capital allocation strategy[423]. - Chemours anticipates significant cash payments for contractual obligations over the next 12 months, funded through operations, available cash, and existing debt financing[420]. - The company expects to maintain sufficient liquidity to meet its obligations through at least May 2026, focusing on growth initiatives and returning cash to shareholders[423]. Environmental and Regulatory Matters - The company has accrued litigation costs of $192 million as of March 31, 2025, which includes settlements with Ohio and Delaware[421]. - Environmental remediation liabilities amounted to $567 million as of March 31, 2025, slightly down from $571 million at the end of 2024[458]. - The five most significant environmental remediation sites account for 83% of total accrued liabilities, with expected spending of $128 million over the next three years for these sites[464]. - The New Jersey Department of Environmental Protection (NJ DEP) has mandated a remediation funding source of $943 million for Chambers Works, primarily for non-PFAS remediation[490]. - A conditional fine of up to €3.7 million has been indicated by DCMR for non-compliance with discharge limits, with a grace period until July 2025[474]. - The company has accrued €1 million related to a penalty from the Dutch ILT agency concerning hydrofluorocarbon reporting errors as of March 31, 2025[475]. - The company has implemented improvements to reporting procedures to comply with hydrofluorocarbon regulations after exceeding its quota[475]. - The company has been ordered to meet specific limits for PFAS discharges or face conditional fines, reflecting increased regulatory scrutiny[473]. - The company submitted a revised NPDES permit application in December 2024 to address discharge exceedances and is expected to incur future capital expenditures related to this[487]. - The company is engaged in ongoing legal discussions with four municipalities regarding environmental-related expenditures, with potential losses deemed probable but not estimable at this time[472]. Sustainability Initiatives - Chemours aims for a 60% absolute reduction in greenhouse gas emissions by 2030 and has set a new Scope 3 target to reduce emissions by 25% per ton of product by 2030[492]. - The Opteon™ product portfolio is projected to result in 325 million tons of avoided carbon dioxide equivalent emissions globally by the end of 2025[494]. - A 60% reduction in Scope 1 and Scope 2 absolute GHG emissions has been achieved, along with a 99% reduction in air and water process emissions of fluorinated organic chemicals[495]. - Chemours' Titanium Technologies business is advancing sustainability goals through the Ti-Pure™ Sustainability product series, focusing on climate impact and resource efficiency[498]. Financial Instruments and Hedging - At March 31, 2025, Chemours had 11 foreign currency forward contracts outstanding with a gross notional U.S. dollar equivalent of $185 million[512]. - For the three months ended March 31, 2025, Chemours recognized net losses of $2 million related to non-designated foreign currency forward contracts[512]. - The company has 185 foreign currency forward contracts under a cash flow hedge program with an aggregate notional U.S. dollar equivalent of $201 million as of March 31, 2025[513]. - A pre-tax loss of $15 million was recognized on the net investment hedge for the three months ended March 31, 2025[514]. - The company entered into a cross-currency swap to convert $600 million of senior unsecured notes due January 2033 into €567 million, with a fair value loss of $11 million as of March 31, 2025[515]. - A pre-tax loss of $16 million was recognized for the cross-currency swap for the three months ended March 31, 2025[515]. - The company has two interest rate swaps with an aggregate notional value of $300 million, resulting in a fair value loss of $4 million as of March 31, 2025[517]. - A pre-tax loss of $1 million was recognized for the interest rate swaps for the three months ended March 31, 2025[517]. - The company recognized a pre-tax gain of $4 million from interest rate swaps during the three months ended March 31, 2024[517].

Financial Performance - First quarter 2025 Net Sales were $1.368 billion, consistent with the prior-year quarter, with a 5% increase in volume offset by a 4% decrease in price [4]. - Net Loss attributable to Chemours was $4 million, or $0.03 per diluted share, compared to Net Income of $54 million, or $0.36 per diluted share in the prior-year quarter [5]. - Adjusted EBITDA for Q1 2025 was $166 million, a decrease of 13% from $191 million in the prior-year quarter [4]. - For Q1 2025, Net Sales were reported at $1,368 million, a slight increase from $1,362 million in Q1 2024 [43]. - The Chemours Company reported a net loss of $4 million for the three months ended March 31, 2025, compared to a net income of $54 million in the same period of 2024 [54]. - Adjusted Net Income for the three months ended March 31, 2025, was $19 million, down from $47 million in the previous year [57]. - The estimated Adjusted EBITDA for the year ending December 31, 2025, ranges from $825 million to $950 million [61]. - The company anticipates a net income attributable to Chemours between $168 million and $263 million for the year ending December 31, 2025 [61]. Segment Performance - TSS segment achieved Net Sales of $466 million, a 3% increase year-over-year, driven by a 10% volume increase, while Opteon™ Refrigerants saw a 40% year-over-year growth in Net Sales [11]. - TT segment Net Sales were $597 million, a 1% increase year-over-year, but Adjusted EBITDA decreased 28% to $50 million due to pricing pressures [14]. - APM segment Net Sales decreased 3% to $294 million, with Adjusted EBITDA increasing 7% to $32 million, reflecting lower costs despite unfavorable currency movements [18]. - The Titanium Technologies segment generated net sales of $597 million, a 6% increase compared to $591 million in Q1 2024 [49]. - The Thermal & Specialized Solutions segment reported net sales of $466 million, reflecting a 12% increase from $454 million in Q4 2024 [49]. - The Advanced Performance Materials segment reported net sales of $294 million, a 9% decrease from $303 million in Q1 2024 [49]. Cash Flow and Debt - Cash used for operating activities was $112 million in Q1 2025, a decrease from $290 million in Q1 2024 [54]. - The company’s cash, cash equivalents, restricted cash, and restricted cash equivalents decreased by $249 million to $514 million as of March 31, 2025 [54]. - As of March 31, 2025, consolidated gross debt was $4.1 billion, with a net leverage ratio of approximately 5.0x on a trailing twelve-month Adjusted EBITDA basis [25]. - The net leverage ratio calculated using non-GAAP earnings was 5x as of March 31, 2025, compared to 3.7x in the previous year [53]. - Free Cash Flows for the three months ended March 31, 2025, were negative $196 million, compared to negative $392 million for the same period in 2024 [60]. - Free cash flow conversion is projected to be in the range of 60-80% in the second half of 2025, assuming the current tariff environment remains unchanged [35]. Future Outlook - For Q2 2025, the company anticipates consolidated Net Sales to increase in the low to mid-teens sequentially, with Adjusted EBITDA expected to rise by 40% to 45% [29]. - The Company expects a sequential Net Sales increase in the high single-digits, primarily driven by seasonal volume increases in western markets [33]. - Adjusted EBITDA is anticipated to increase in the low 40% range sequentially due to seasonal volume increases and operational improvements following cold weather downtime at U.S. sites [33]. - For the full year 2025, the Company projects Adjusted EBITDA between $825 million and $950 million, with capital expenditures expected to range from $225 million to $275 million [35]. Corporate Actions - The company signed a manufacturing agreement with Navin Fluorine International, Ltd. for two-phase immersion cooling fluid [9]. - Chemours announced a 65% reduction in its quarterly dividend to $0.0875 per share to enhance balance sheet flexibility [28]. - The Company has approximately 6,000 employees and operates 28 manufacturing sites globally, serving around 2,500 customers in approximately 110 countries [37]. - The Company emphasizes the use of non-GAAP financial measures to provide greater transparency regarding its financial performance and operational decision-making [38]. - The company incurred litigation-related charges of $592 million for the twelve months ended March 31, 2024, primarily related to a class action suit settlement [56]. - Restructuring and other costs for the year ending December 31, 2025, are estimated at $24 million [62].

Company Overview - Chemours (CC) is expected to report a year-over-year decline in earnings, with a projected earnings per share (EPS) of $0.19, reflecting a decrease of 40.6% compared to the previous year [3] - Revenue for the quarter is anticipated to be $1.36 billion, which represents a slight increase of 0.4% from the same quarter last year [3] Earnings Expectations - The earnings report is scheduled for release on May 6, 2025, and the stock price may react positively if the results exceed expectations, while a miss could lead to a decline [2] - The consensus EPS estimate has been revised down by 0.87% over the last 30 days, indicating a bearish sentiment among analysts [4] Earnings Surprise Prediction - The Most Accurate Estimate for Chemours is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -25.33%, which suggests a challenging outlook for beating the consensus EPS estimate [10][11] - Historically, Chemours has beaten consensus EPS estimates three out of the last four quarters, with a recent surprise of +10% when it reported earnings of $0.11 per share against an expectation of $0.10 [12][13] Industry Comparison - In the Zacks Chemical - Diversified industry, DuPont de Nemours (DD) is expected to report earnings of $0.95 per share, indicating a year-over-year increase of 20.3%, with revenues projected at $3.04 billion, up 3.7% from the previous year [17] - DuPont's consensus EPS estimate has been revised down by 2.4% over the last 30 days, and it currently holds an Earnings ESP of -0.32%, making it difficult to predict a beat against the consensus [18]

Core Insights - Chemours shares have declined approximately 14% since the last earnings report, underperforming the S&P 500 [1] - The consensus estimate for Chemours has decreased by 62.75% over the past month, indicating a negative trend in estimates [2] Financial Performance - The most recent earnings report highlighted a downward trend in estimates, suggesting potential challenges ahead for Chemours [4] - Chemours currently holds a Zacks Rank of 3 (Hold), indicating expectations for an in-line return in the coming months [4] Investment Scores - Chemours has a subpar Growth Score of D and a Momentum Score of F, but it received an A for Value, placing it in the top 20% for this investment strategy [3] - The aggregate VGM Score for Chemours is C, which is relevant for investors not focused on a single strategy [3]

Group 1 - The Chemours Company (CC) has formed an alliance with Energy Fuels Inc. to enhance the supply chains for rare earth and critical minerals in response to rising demand [1][2] - Energy Fuels is anticipated to produce large quantities of rare earth elements, titanium ilmenite, and zircon minerals in the upcoming years, while Chemours is involved in mining and separating heavy mineral sands in Florida and Georgia [2] - The collaboration exemplifies the mining industry's commitment to reshoring mineral supply chains and increasing domestic production to satisfy modern society's significant mineral demands [3] Group 2 - Chemours expects its full-year 2025 adjusted EBITDA to be between $825 million and $975 million, with capital expenditures projected between $250 million and $300 million [4] - CC's stock has declined by 46.4% over the past year, compared to a 13.2% decline in the industry [3] - CC currently holds a Zacks Rank of 3 (Hold), while better-ranked stocks in the Basic Materials sector include Ingevity Corporation (NGVT), Axalta Coating Systems (AXTA), and Carpenter Technology Corporation (CRS) [5]

Core Insights - The Chemours Company reported a net loss of $8 million or 5 cents per share for Q4 2024, an improvement from a loss of $18 million or 12 cents in the same quarter last year [1] - Adjusted earnings came in at 11 cents per share, beating the Zacks Consensus Estimate of 10 cents [1] - Fourth-quarter net sales were $1,359 million, reflecting a 1% decline year-over-year, falling short of the Zacks Consensus Estimate of $1,359.8 million [2] Financial Performance - Adjusted EBITDA rose 2% year-over-year to $179 million, driven by cost savings from the Titanium Technologies Transformation Plan and increased volumes in Thermal & Specialized Solutions [3] - For FY 2024, net sales totaled $5,782 million, a decline of 4.9% from the previous year, with adjusted net income dropping to $182 million from $425 million [7] - Cash provided by operating activities in Q4 2024 was $138 million, down from $482 million in the prior-year quarter [8] Segment Performance - The Titanium Technologies division reported revenues of $632 million, a 3% decrease from the previous year, primarily due to a 2% decrease in pricing and a 1% fall in volume [4] - The Thermal & Specialized Solutions segment saw a 3% year-over-year revenue increase to $390 million, driven by a 7% increase in volume, although it fell short of estimates [5] - Advanced Performance Materials revenues amounted to $324 million, a decline of approximately 1% year-over-year, primarily due to a 3% drop in price [6] Outlook - The company expects full-year 2025 adjusted EBITDA to be between $825 million and $975 million, with capital expenditures projected between $250 million and $300 million [10] Stock Performance - Chemours shares have decreased by 39.7% over the past year, contrasting with a 0.8% decline in the industry [11]

Core Points - The article discusses the investment positions held by the author in specific companies, indicating a beneficial long position in shares of CC and BASFY [1] - It emphasizes the importance of conducting due diligence and research before making any investment decisions, particularly in high-risk trading styles [2] - The article clarifies that past performance does not guarantee future results and that the views expressed may not reflect those of the platform as a whole [3] Summary by Categories - **Investment Positions** - The author has a beneficial long position in shares of CC and BASFY, either through stock ownership, options, or other derivatives [1] - **Investment Advice and Due Diligence** - The article stresses that it is not financial advice and that investors should perform their own due diligence and research prior to any investment [2] - It highlights the risks associated with short-term trading, options trading, and futures trading, which may not be suitable for investors with limited capital or experience [2] - **Performance and Opinions** - The article notes that past performance is not a guarantee of future results, and the opinions expressed may not represent the views of the platform as a whole [3]

Chemours (CC) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.31 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 10%. A quarter ago, it was expected that this chemical company would post earnings of $0.32 per share when it actually produced earnings of $0.40, delivering a surprise of 25%.Over the last four quarters, the company has su ...